NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is to put Roche's Tarceva (erlotinib) under the microscope as a first-line option for treating adults with epidermal growth factor receptor (EGFR) mutation positive, locally advanced or metastatic non-small-cell lung cancer (NSCLC). The institute has recently put out for consultation a draft appraisal scope for Tarceva, as well as one for Allergan's Botox and three for Celgene's Revlimid.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.